Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nephropathy in type 1 diabetes.

Michel Marre1

  • 1Service d'Endocrinologie Diabétologie Métabolisme Nutrition, Centre Hospitalier Universitaire Bichat-Claude Bernard, Paris, France. michel.marre@bch.ap-hop-paris.fr

Seminars in Vascular Medicine
|October 14, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of high intensity physical activity compared to routine counseling on renal function decline in patients with type 2 diabetes at high risk for kidney disease - the ACTIDIANE randomized controlled trial.

Diabetes & metabolism·2026
Same author

Estimated Glucose Disposal Rate and Risk of Vascular Events and Death in Type 2 Diabetes in the ADVANCE Study.

Diabetes, obesity & metabolism·2026
Same author

Risk score for lower-limb amputation and its ability to predict major kidney and cardiovascular events in people with type 1 diabetes.

Cardiovascular diabetology·2026
Same author

Lipoprotein levels and statin treatment related to dementia and cognitive decline in individuals with type 2 diabetes: an observational analysis from the ADVANCE study.

Cardiovascular diabetology·2025
Same author

Relationship between time-varying achieved HbA<sub>1c</sub> and risk of coronary artery disease events among common haptoglobin phenotype groups with type 2 diabetes: the ADVANCE study.

BMJ open diabetes research & care·2025
Same author

Genome-Wide Association Study of Quantitative Kidney Function in 52,531 Individuals with Diabetes Identifies Five Diabetes-Specific Loci.

Journal of the American Society of Nephrology : JASN·2025

Diabetic nephropathy, a major complication of type 1 diabetes, involves glomerular damage. Genetic factors influence risk, and renin-angiotensin system blockers show promise in improving outcomes.

Area of Science:

  • Nephrology
  • Endocrinology
  • Diabetology

Background:

  • Diabetic nephropathy is a critical complication of type 1 diabetes, stemming from glucose-induced hemodynamic changes in the glomerulus.
  • Early stages of diabetic nephropathy are marked by glomerulosclerosis, driven by increased expression of cytokines such as tumor growth factor beta1.
  • Individual susceptibility to nephropathy varies, likely due to genetic polymorphisms influencing disease pathogenesis.

Purpose of the Study:

  • To explore the pathophysiological underpinnings of diabetic nephropathy in type 1 diabetes.
  • To investigate the role of genetic factors in modulating the risk and progression of nephropathy.
  • To evaluate the efficacy of renin-angiotensin system blockers in managing type 1 diabetes nephropathy.

Main Methods:

Related Experiment Videos

  • Review of pathophysiological mechanisms linking hyperglycemia to glomerular damage.
  • Analysis of genetic polymorphisms associated with diabetic nephropathy.
  • Assessment of clinical data on the effectiveness of renin-angiotensin system blockers.

Main Results:

  • Glucose-induced preglomerular vasodilation adversely affects glomerular hemodynamics, initiating nephropathy.
  • Tumor growth factor beta1 expression is implicated in the early onset of glomerulosclerosis.
  • Genetic variations play a role in determining individual risk for developing diabetic nephropathy.

Conclusions:

  • Understanding the pathogenesis of diabetic nephropathy is crucial for risk stratification.
  • Genetic predisposition influences the course of diabetic nephropathy.
  • Renin-angiotensin system blockers are effective in improving the prognosis of type 1 diabetes nephropathy.